**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 82159

**Manuscript Type:** LETTER TO THE EDITOR

**T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation**

Yang T *et al.* Tryptophan metabolism in pancreatic cancer

Ting Yang, Qiao-Qi Li, Yong-Mei Liu, Biao Yang

**Ting Yang, Qiao-Qi Li, Biao Yang,** Department of Abdominal Oncology, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

**Yong-Mei Liu,** Division of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

**Author contributions:** Yang T, Li QQ, Liu YM, and Yang B designed the research study; Yang T and Li QQ performed the research; Yang T, Li QQ, and Yang B analyzed the data and wrote the manuscript; All authors read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 82200695

**Corresponding author: Biao Yang, MD, PhD, Professor, Surgeon, Teacher,** Department of Abdominal Oncology, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. landayb@163.com

**Received:** December 7, 2022

**Revised:** February 10, 2023

**Accepted:** April 4, 2023

**Published online:**

**Abstract**

Several studies have shown that the immune system is highly regulated by tryptophan metabolism, which serves as an immunomodulatory factor. The indoleamine 2,3-dioxygenase 1 (IDO1), as an intracellular enzyme that participates in metabolism of the essential amino acid tryptophan in the kynurenine pathway, is an independent prognostic marker for pancreatic cancer (PC). First, overexpression of IDO1 inhibits the maturation of dendritic cells and T-cell proliferation in the liver and spleen. Second, the high expression of kynurenine induces and activates the aryl hydrocarbon receptor, resulting in upregulated programmed cell death protein 1 expression. Third, the induction of IDO1 can lead to loss of the T helper 17 cell/regulatory T cell balance, mediated by the proximal tryptophan catabolite from IDO metabolism. In our study, we found that overexpression of IDO1 upregulated CD8+ T cells and reduced natural killer T cells in pancreatic carcinoma in mice. Hence, it may be essential to pay more attention to tryptophan metabolism in patients, especially those who are tolerant to immunotherapy for PC.

**Key Words:** Immunosuppression; Pancreatic cancer stroma; T cell; Tryptophan metabolism; Xxx

Yang T, Li QQ, Liu YM, Yang B. T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation. *World J Gastroenterol* 2023; In press

**Core Tip:** There are numerous lines for evidence for tryptophan metabolism, which serves as an immunomodulatory factor. Indoleamine2,3-dioxygenase1 (IDO1) overexpression inhibits the maturation of dendritic cells and T-cell proliferation in the spleen. The high expression of kynurenine induces and activates the aryl hydrocarbon receptor, resulting in upregulated programmed cell death protein 1 expression. The induction of IDO1 can lead to loss of T helper 17 cell/regulatory T cell balance. We also found that overexpression of IDO1 upregulated CD8+ T cells and reduced natural killer T cells in PC in mice.

**TO THE EDITOR**

We have an interest in the recently published article by Goulart *et al*[1],which summarized the pancreatic cancer (PC) immune landscape, T-cell interactions and immune dysfunction, T-cell phenotype and functions, T-cell exhaustion, and immunotherapy in PC. In this review, Goulart *et al* stated that immune cells including CD8+ T, natural killer (NK) cells, T helper 17 cells (Th17), and regulatory T cells (Tregs) are regulated by different cytokine factors. However, several studies have shown that the immune system is highly regulated by tryptophan metabolism. Indoleamine 2,3-dioxygenase 1 (IDO1), as an intracellular enzyme that participates in the metabolism of the essential amino acid tryptophan in the kynurenine (Kyn) pathway, is an independent prognostic marker for PC. There are numerous lines of evidence for tryptophan metabolism, which serves as an immunomodulatory factor. First, IDO1 overexpression inhibits the maturation of CD11c and dendritic cells, and T-cell proliferation in the liver and spleen[2]. Second, the high expression of Kyn induces and activates the aryl hydrocarbon receptor (AhR), resulting in upregulated programmed cell death protein 1 expression. Inhibition of the Kyn-AhR pathway can enhance the efficacy of antitumor adoptive T-cell therapy and reduce the rate of migration and invasion in both tumor-bearing mice and patients with cancer[3]. In *in* *vivo* experiments, inactivation of the Kyn-AhR pathway showed amelioration of IDO1-mediated immunosuppression[4]. In a clinical study, high expression of the AhR transcript was correlated with reduced CD8 T-cell infiltration and worse outcomes in patients with PC[5]. Third, the induction of IDO1 can lead to loss of the Th17/Treg balance *in vivo*. Similarly, loss of the Th17/Treg balance is mediated by the proximal tryptophan catabolite from IDO metabolism[6]. In our study, we found that overexpression of IDO1 upregulated CD8+ T cells and reduced NK T cells in both hepatic cancer and PC in mice. Hence, it may be essential to pay more attention to tryptophan metabolism in patients with PC, especially those who are tolerant to immunotherapy.

**REFERENCES**

1 **Goulart MR**, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM. T cells in pancreatic cancer stroma. *World J Gastroenterol* 2021; **27**: 7956-7968 [PMID: 35046623 DOI: 10.3748/wjg.v27.i46.7956]

2 **Mo C**, Xie S, Liu B, Zhong W, Zeng T, Huang S, Lai Y, Deng G, Zhou C, Yan W, Chen Y, Huang S, Gao L, Lv Z. Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis. *Cell Death Dis* 2021; **12**: 16 [PMID: 33414436 DOI: 10.1038/s41419-020-03277-0]

3 **Liu Y**, Liang X, Dong W, Fang Y, Lv J, Zhang T, Fiskesund R, Xie J, Liu J, Yin X, Jin X, Chen D, Tang K, Ma J, Zhang H, Yu J, Yan J, Liang H, Mo S, Cheng F, Zhou Y, Zhang H, Wang J, Li J, Chen Y, Cui B, Hu ZW, Cao X, Xiao-Feng Qin F, Huang B. Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation. *Cancer Cell* 2018; **33**: 480-494.e7 [PMID: 29533786 DOI: 10.1016/j.ccell.2018.02.005]

4 **Liang H**, Li T, Fang X, Xing Z, Zhang S, Shi L, Li W, Guo L, Kuang C, Liu H, Yang Q. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer. *Cancer Lett* 2021; **522**: 32-43 [PMID: 34520819 DOI: 10.1016/j.canlet.2021.09.012]

5 **Newman AC**, Falcone M, Huerta Uribe A, Zhang T, Athineos D, Pietzke M, Vazquez A, Blyth K, Maddocks ODK. Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. *Mol Cell* 2021; **81**: 2290-2302.e7 [PMID: 33831358 DOI: 10.1016/j.molcel.2021.03.019]

6 **Favre D**, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. *Sci Transl Med* 2010; **2**: 32ra36 [PMID: 20484731 DOI: 10.1126/scitranslmed.3000632]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 7, 2022

**First decision:** January 22, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu X, China; Zeng C, United States **S-Editor:** Liu GL **L-Editor:** Filipodia **P-Editor:** Liu GL